Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metabolic effects of antipsychotics in children.

Trial Profile

Metabolic effects of antipsychotics in children.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Risperidone (Primary)
  • Indications Behavioural disorders; Psychotic disorders
  • Focus Pharmacodynamics
  • Acronyms MEAC
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Aug 2011 Additional lead trial investigator (Ginger Nicol) identified as reported by ClinicalTrials.gov.
    • 02 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top